Infectious disease epidemics are composed of chains of transmission, but little is known about how co-circulating transmissions vary in size.
Understanding these features could help to target interventions and track variants and their hosts with different impacts.
Did you know that there are currently 154 vaccine candidates in pre-clinical trials?
There are also 21 in Phase I trials, 12 in Phase II trials and 11 awaiting approval following Phase III trials.
The new variant of the SARS-CoV-2 virus known as the B.1.1.7 variant has a total of 23 mutations.
Six of these cause no change in the amino acids, but of the remaining 17, eight affect the spike protein. Due to this, some scientists believe the B.1.1.7 variant has a higher rate of transmissibility.
Bayer joined CureVac to support the development of the messenger RNA (mRNA) based COVID-19 vaccine.
The vaccine is now moving into its Phase III trial and plans to enroll more than 35,000 people.
Last month, NIAID announced the commencement of the Phase III trial of the Novavax investigational vaccine.
The trial will look to evaluate the effectiveness and immune response of the vaccine candidate.
A recent study revealed that UV LED lights effectively kill a human Coronavirus.
If future research finds that they are also effective against SARS-CoV-2, this technology could be an inexpensive way to disinfect hospitals and other industrial settings.
Although we are still living in a world largely dominated by COVID-19, here at Baker, we feel it’s important to still continue to support those working in patient and clinical care across the globe.
As vaccines are rolled out in many countries, the hope for a new normality could soon be on the horizon. At Baker, we have been #SupportingScience since 1951 and with new vaccines, therapeutics and discoveries now worldwide, we will continue to do so now more than ever!
Research has found that a genetically altered vaccine for yellow fever could protect against COVID-19.
It appears to provide protection after a single shot, whereas other SARS-CoV-2 vaccines require two doses, one month apart.
As part of our #SupportingScience campaign, Dr. Ox is launching a new interview series in January 2021.
Make sure you subscribe, as Baker’s Director of Scientific Applications, Krista Rantanen Ph.D. poses some unexpected questions to the leading scientists of our time!
We would like to wish you a Happy Holidays and a wonderful New Year.
We look forward to seeing you in 2021!
AstraZeneca and The University of Oxford released results from its Phase 3 analysis of its COVID-19 vaccine candidate, AZD1222.
Drawn from two separate regimens, a half dose giving 90% efficacy and two full doses giving 62% efficacy, the pooled efficacy rate totalled 70%. Discover more.
Sign up to our monthly newsletter to stay up to date on everything that’s going on at Baker.